Galderma is set to trial the usage of Soolantra and Oracea in combination to treat sufferers of severe rosacea.
What is Severe Rosacea?
Severe rosacea is taken here to be participants with at least 20 but not more than 70 papules and pustules. The trial will aim to show that the addition of Oracea to a topical regime of Soolantra will offer a significant benefit.
By trialing Soolantra with and without Oracea, Galderma hope to show that the combination of the two treatments offers a proven regime.
Galderma’s Big Guns
Galderma has an impressive rosacea portfolio (Soolantra, Mirvaso, Metrogel, Oracea, Cetaphil), and it is beneficial to be able to promote the combination of treatments as `extra effective’. Metrogel in combination with Oracea has attracted research interest in the past with Galderma, now the introduction of Soolantra offers Galderma the opportunity to prove that this combination is the new best-in-class treatment regime.
Oracea Soolantra Association in Patients With Severe Rosacea
Efficacy Comparison of Ivermectin 1% Topical Cream Associated With Doxycycline 40 mg Modified Release (MR) Capsules Versus Ivermectin 1% Topical Cream Associated With Placebo in the Treatment of Severe Rosacea
Primary Outcome Measure: Efficacy (Percent change from Baseline in Inflammatory Lesion count)
Drug: Ivermectin 1% cream
Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks
Drug: Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules 1 Capsule once-daily for 12 weeks vs. Placebo